PDF(Pubmed)
Abstract：
UNASSIGNED: Pulmonary vein stenosis (PVS) is a severe complication of atrial fibrillation (AF) ablation resulting in narrowing of affected pulmonary veins (PVs). Interventional treatment consists of angioplasty with or without PV stenting. The optimal postprocedural antithrombotic therapy is not known.
UNASSIGNED: To investigate the impact of antithrombotic medical therapy on recurrence of PVS after PV angioplasty.
UNASSIGNED: A retrospective study of patients undergoing PV angioplasty with or without stent implantation in two German centers was performed. Postinterventional antithrombotic therapy consisted of either dual antiplatelet therapy (DAPT) or a combination of oral anticoagulation with single or dual antiplatelet therapy for 3-12 months after intervention. Angiographic follow-up was recommended 3, 6, and 12 months after intervention and in case of symptom recurrence.
UNASSIGNED: Thirty patients underwent treatment of 42 PVS. After intervention, twenty-eight patients received triple therapy and 14 patients received dual therapy/DAPT; restenosis occurred in 5/22 (22.7%) patients with triple therapy and 8/14 (57.1%) patients with dual therapy/DAPT PV (p = .001). Estimated freedom from PV restenosis after 500 days was 18.8 ± 15.8% (dual therapy/DAPT) and 76.2 ± 10.5% (triple therapy) (p = .003). Univariate regression analysis revealed postprocedural medication as a significant risk factor for restenosis (p = .019). No bleeding events occurred regardless of applied antithrombotic therapy.
UNASSIGNED: Triple antithrombotic therapy after PV angioplasty is associated with less frequent restenosis as compared to dual antiplatelet therapy or a combination of anticoagulation and single antiplatelet therapy. No severe bleeding events occurred in patients on triple therapy. These findings need to be confirmed in larger patient cohorts.
UNASSIGNED: To investigate the impact of antithrombotic medical therapy on recurrence of PVS after PV angioplasty.
UNASSIGNED: A retrospective study of patients undergoing PV angioplasty with or without stent implantation in two German centers was performed. Postinterventional antithrombotic therapy consisted of either dual antiplatelet therapy (DAPT) or a combination of oral anticoagulation with single or dual antiplatelet therapy for 3-12 months after intervention. Angiographic follow-up was recommended 3, 6, and 12 months after intervention and in case of symptom recurrence.
UNASSIGNED: Thirty patients underwent treatment of 42 PVS. After intervention, twenty-eight patients received triple therapy and 14 patients received dual therapy/DAPT; restenosis occurred in 5/22 (22.7%) patients with triple therapy and 8/14 (57.1%) patients with dual therapy/DAPT PV (p = .001). Estimated freedom from PV restenosis after 500 days was 18.8 ± 15.8% (dual therapy/DAPT) and 76.2 ± 10.5% (triple therapy) (p = .003). Univariate regression analysis revealed postprocedural medication as a significant risk factor for restenosis (p = .019). No bleeding events occurred regardless of applied antithrombotic therapy.
UNASSIGNED: Triple antithrombotic therapy after PV angioplasty is associated with less frequent restenosis as compared to dual antiplatelet therapy or a combination of anticoagulation and single antiplatelet therapy. No severe bleeding events occurred in patients on triple therapy. These findings need to be confirmed in larger patient cohorts.
摘要：
未经证实：肺静脉狭窄（PVS）是心房颤动（AF）消融的严重并发症，导致受影响的肺静脉（PV）变窄。介入治疗包括有或没有PV支架的血管成形术。最佳的术后抗血栓治疗尚不清楚。
UNASSIGNED：探讨抗血栓药物治疗对PV血管成形术后PVS复发的影响。
UNASSIGNED：在德国的两个中心进行了一项回顾性研究，研究对象是接受PV血管成形术伴或不伴支架植入的患者。介入后抗血栓治疗包括双重抗血小板治疗（DAPT）或口服抗凝与单一或双重抗血小板治疗的组合，干预后3-12个月。建议在干预后3、6和12个月以及症状复发后进行血管造影随访。
未经授权：30例患者接受了42例PVS的治疗。干预后,28例患者接受三联疗法,14例患者接受双联疗法/DAPT;5/22(22.7%)例患者接受三联疗法,8/14(57.1%)例患者接受双联疗法/DAPTPV(p=.001)发生再狭窄.500天后肺静脉再狭窄的估计自由为18.8±15.8%(双联疗法/DAPT)和76.2±10.5%(三联疗法)(p=.003)。单因素回归分析显示术后药物治疗是再狭窄的重要危险因素（p=0.019）。无论应用抗血栓治疗，均未发生出血事件。
UNASSIGNED：与双重抗血小板治疗或联合抗凝和单一抗血小板治疗相比，PV血管成形术后三重抗血栓治疗的再狭窄频率较低。三联疗法患者未发生严重出血事件。这些发现需要在更大的患者队列中得到证实。
UNASSIGNED：探讨抗血栓药物治疗对PV血管成形术后PVS复发的影响。
UNASSIGNED：在德国的两个中心进行了一项回顾性研究，研究对象是接受PV血管成形术伴或不伴支架植入的患者。介入后抗血栓治疗包括双重抗血小板治疗（DAPT）或口服抗凝与单一或双重抗血小板治疗的组合，干预后3-12个月。建议在干预后3、6和12个月以及症状复发后进行血管造影随访。
未经授权：30例患者接受了42例PVS的治疗。干预后,28例患者接受三联疗法,14例患者接受双联疗法/DAPT;5/22(22.7%)例患者接受三联疗法,8/14(57.1%)例患者接受双联疗法/DAPTPV(p=.001)发生再狭窄.500天后肺静脉再狭窄的估计自由为18.8±15.8%(双联疗法/DAPT)和76.2±10.5%(三联疗法)(p=.003)。单因素回归分析显示术后药物治疗是再狭窄的重要危险因素（p=0.019）。无论应用抗血栓治疗，均未发生出血事件。
UNASSIGNED：与双重抗血小板治疗或联合抗凝和单一抗血小板治疗相比，PV血管成形术后三重抗血栓治疗的再狭窄频率较低。三联疗法患者未发生严重出血事件。这些发现需要在更大的患者队列中得到证实。
